Cell Signaling Technology

Product Pathways - Tyrosine Kinase / Adaptors

Bcr Antibody #3902

Applications Reactivity Sensitivity MW (kDa) Source
W IF-IC F H M R Pg Endogenous 130, 160 (Bcr); 210 (Bcr-Abl) Rabbit

Applications Key:  W=Western Blotting  IF-IC=Immunofluorescence (Immunocytochemistry)  F=Flow Cytometry
Reactivity Key:  H=Human  M=Mouse  R=Rat  Pg=Pig
Species cross-reactivity is determined by western blot. Species enclosed in parentheses are predicted to react based on 100% sequence homology.

Protocols

Specificity / Sensitivity

Bcr Antibody detects endogenous levels of total Bcr as well as the 210 kDa Bcr-Abl fusion protein.

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to the amino-terminal sequence of human Bcr. Antibodies are purified by protein A and peptide affinity chromatography.

Western Blotting

Western Blotting

Western blot analysis of extracts from K562, MCF-7 and HepG2 cells, using Bcr Antibody.

Flow Cytometry

Flow Cytometry

Flow cytometric analysis of K562 cells, untreated (green) or Gleevec® (STI571)-treated (blue), using Bcr Antibody compared to a nonspecific negative control antibody (red).

IF-IC

IF-IC

Immunofluorescent analysis of PAE cells, using Bcr Antibody (left) or the same antibody preincubated with Bcr-specific peptide (right).


Background

The Bcr gene was orginally identified by its presence in the chimeric Bcr-Abl oncogene (1). The amino-terminal region of Bcr contains an oligomerization domain, a serine/threonine kinase domain, and a region that binds SH2 domains. The middle of the protein has a PH domain and a region of sequence similarity to the guanine nucleotide exchange factors for the Rho family of GTP binding proteins. The carboxy-terminal region may be involved in a GTPase activating function for the small GTP-binding protein Rac (2,3). The function of wild type Bcr in cells remains unclear. PDGF receptor may use Bcr as a downstream signaling mediator (4). Research studies have shown that the Bcr-Abl fusion results in production of a constitutively active tyrosine kinase, which causes chronic myelogenous leukemia (CML) (5). Tyr177 of Bcr is phosphorylated in the Bcr-Abl fusion protein, which plays an important role in transforming the activity of Bcr-Abl (6). Phosphorylated Tyr177 provides a docking site for Gab2 and GRB2 (7,8).

  1. Groffen, J. et al. (1984) Cell 36, 93-99.
  2. Maru, Y. et al. (1991) Cell 67, 459-468.
  3. Che, W. et al. (2001) Circulation 104, 1399-1406.
  4. Abe, J. I. et al. (2001) Ann. N.Y. Acad. Sci. 947, 341-343.
  5. Voncken, J. W. et al. (1995) Cell 80, 719-728.
  6. He, Y. et al. (2002) Blood 99, 2957-2968.
  7. Sattler, M. et al. (2002) Cancer Cell 1, 479-492.
  8. Warmuth, M. et al. (1995) J. Biol. Chem. 272, 33260-33270.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products

For Research Use Only. Not For Use In Diagnostic Procedures.

Products